Premium
Esomeprazole in the treatment of Helicobacter pylori
Author(s) -
Laine L.
Publication year - 2002
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1046/j.1365-2036.16.s4.13.x
Subject(s) - esomeprazole , omeprazole , proton pump inhibitor , clarithromycin , helicobacter pylori , amoxicillin , medicine , gastroenterology , antibiotics , microbiology and biotechnology , biology
Summary Proton pump inhibitor‐based triple therapy is the most commonly used treatment for eradication of Helicobacter pylori , with pooled eradication rates of approximately 90%. In the USA, per protocol eradication rates with 10‐day proton pump inhibitor‐based triple therapy are approximately 85%. Esomeprazole, a new proton pump inhibitor that is the S‐isomer of omeprazole and produces a greater inhibition of acid secretion than omeprazole, has recently been evaluated in the treatment of H. pylori . Seven‐day twice daily triple therapy with esomeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg provided intention‐to‐treat eradication rates of 86–90% and per protocol eradication rates of 90–91% in duodenal ulcer patients in Europe and Canada. Ten‐day triple therapy with esomeprazole 40 mg q.d.s., amoxicillin 1 g b.d. and clarithromycin 500 mg b.d. achieved intention‐to‐treat eradication rates of 77–78% and per protocol eradication rates of 84–85% in USA duodenal ulcer patients. Thus, esomeprazole triple therapy with amoxicillin and clarithromycin is effective in the treatment of H. pylori , with eradication rates comparable to previously studied proton pump inhibitor‐based triple therapies.